V
Power Law company profile
Verve Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2018 · IPO 2021 Unicorn
Global footprint
Where Verve Therapeutics has talent and traffic
AI talent share
1.2%
of workforce is AI talent
(2 of 161 staff)
(2 of 161 staff)
Core AI10.62%
Other AI10.62%
Non-AI workforce15998.76%
Web traffic by country
9.3K
monthly visits
across markets
across markets
🇺🇸 United States63.4%
🇬🇧 United Kingdom18.3%
🇮🇳 India18.3%
Patent intelligence
$22M patent portfolio · 12 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$22M
3.8% of valuation · 36.2× smaller than top peer BioNTech ($780M)
12 active patent families
Where Verve Therapeutics innovates
Molecular biologyTarget geneNanoparticleRNACell biology
Above peer median on Strategic
Quality vs same-sector peers
Verve Therapeutics on the five Patsnap quality dimensions
Verve Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Verve Therapeutics concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Verve Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Verve Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.